Revenue Breakdown
Composition ()
No data
Revenue Streams
Collplant Biotechnologies Ltd (CLGN) generates its revenue primarily from Revenues from the sales of goods, which accounts for 100.0% of total sales, equivalent to $179.00K. Understanding this concentration is critical for investors evaluating how CLGN navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Collplant Biotechnologies Ltd maintains a gross margin of -249.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4554.55%, while the net margin is -4523.38%. These profitability ratios, combined with a Return on Equity (ROE) of -92.74%, provide a clear picture of how effectively CLGN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CLGN competes directly with industry leaders such as NXL and HSCS. With a market capitalization of $7.27M, it holds a significant position in the sector. When comparing efficiency, CLGN's gross margin of -249.35% stands against NXL's 78.25% and HSCS's 58.33%. Such benchmarking helps identify whether Collplant Biotechnologies Ltd is trading at a premium or discount relative to its financial performance.
